Michael J. Fitzpatrick
52 IP cases indexed. Covers patent matters.
Cases Presided Over
52 cases indexed | Page 2 of 2
Medela LLC et al. v.M.E.A.C. Engineering Ltd.
Medela and M.E.A.C. Engineering settled their IPR dispute over patent 8,858,534 B2. The Board terminated the proceeding before any trial, keeping the settlement confidential.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial, resulting in the Board terminating the proceedings. The joint motion and stipulation with prejudice ended the challenge to patent 10,171,433.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial, resulting in a Board‑ordered termination of IPR2025-00752 covering patent 10,044,689.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding that the asserted claims were not obvious or anticipated by the prior art. The Board specifically rejected arguments linking Cantor to spatial analysis in tissue sections.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
Curio Bioscience, Inc.'s IPR challenge against Prognosys and 10X Genomics was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing on grounds of obviousness (over Cantor/Armani) and anticipation (by Frisen).
Guardant Health, Inc. v.Cold Spring Harbor Laboratory
Guardant Health’s IPR resulted in all 28 claims of the 10,697,013 B1 patent being held unpatentable for obviousness over prior‑art tagging methods. The Board affirmed the petitioner’s combination of Linnarsson and McCloskey references.
Guardant Health, Inc. v.Cold Spring Harbor Laboratory
Guardant Health’s IPR against the ’013 single‑cell sequencing patent resulted in the Board finding all 28 claims unpatentable as obvious over prior publications by Linnarsson and McCloskey. The petition’s obviousness arguments were accepted and the patent owner’s defenses were rejected.
Skechers U.S.A., Inc. v.Nike, Inc.
Skechers U.S.A., Inc.'s IPR challenge against Nike, Inc.'s footwear patent was denied by the PTAB. The Board found that Petitioner failed to meet the threshold burden of showing a reasonable likelihood of prevailing on any unpatentability challenge.
Skechers U.S.A., Inc. v.Nike, Inc.
Skechers U.S.A., Inc.'s IPR challenge against Nike, Inc.'s footwear patent was denied by the PTAB due to failure to meet the reasonable likelihood of prevailing standard. The Board rejected key claim constructions and found that prior art references did not adequately disclose the claimed integral knit tongue feature.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to institute IPR against Seikagaku Corporation's patent (11236318) based on grounds of lack of written description and obviousness. The Board found sufficient evidence at this preliminary stage, allowing the challenge to proceed into full litigation.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS, INC. successfully secured institution of its IPR against Helsinn Healthcare S.A.'s patent (9186357) for anti-emetic agents. The Board found a reasonable likelihood that several claims would be unpatentable over prior art, specifically regarding the combination of triple-drug CINV treatment and superior NK antagonists.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR proceedings against Helsinn Healthcare S.A.'s anti-emetic patent (8623826). The Board found a reasonable likelihood of prevailing on independent claim 19, allowing the challenge based on obviousness over prior art like MASCC and Hoffmann.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB to institute IPR proceedings against Helsinn Healthcare S.A.'s patent covering anti-emetic agents for oncology treatment. The Board found a reasonable likelihood that numerous claims would be unpatentable under 35 U.S.C. § 103 based on prior art references.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR against Helsinn Healthcare's '515 patent covering anti-emetic agents. The Board found a reasonable likelihood of prevailing based on obviousness (103) and prior art, allowing the challenge to proceed.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB that multiple claims of Helsinn Healthcare's anti-emetic patent were unpatentable. The Board granted institution based on obviousness (103) over several prior art references, paving the way for a full trial.
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA, LLC successfully petitioned against Smart Denture Conversions, LLC's patent, leading to institution of IPR proceedings. The Board found a reasonable likelihood that claims are unpatentable under both anticipation (102) and obviousness (103).
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA successfully petitioned for institution in a Post-Grant Review challenging Smart Denture Conversions' dental implant patent (12156781). The Board found likelihood of unpatentability based on indefiniteness and lack of written description/enablement. This sets a precedent regarding the sufficiency of disclosure in complex medical device claims.
Intersect ENT, Inc. et al. v.New Amsterdam, LLC
Intersect ENT and New Amsterdam settled their IPR dispute over U.S. Patent 6,916,483, filing a joint motion that led the PTAB to terminate the proceeding before trial.
Solventum Corporation v.M.E.A.C. Engineering Ltd.
Solventum Corporation and M.E.A.C. Engineering reached a settlement that led to the termination of IPR2024-01001 before any trial was instituted. The Board granted the motion to terminate and ordered the settlement agreement to remain confidential.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial, leading the PTAB to terminate IPR2025-00697 and related proceedings. The settlement was documented via a Joint Stipulation for Dismissal with Prejudice filed in federal court.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial. The Board terminated the proceeding on the parties' joint motion.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their dispute over U.S. Patent 11,070,530, leading to a joint motion that terminated the IPR proceeding before it was instituted.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.